Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) and Cosmos Health (NASDAQ:COSM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.
Valuation and Earnings
This table compares Enanta Pharmaceuticals and Cosmos Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enanta Pharmaceuticals | $65.32 million | 6.12 | -$81.89 million | ($2.59) | -5.31 |
| Cosmos Health | $65.27 million | 0.22 | -$19.15 million | ($0.64) | -0.37 |
Profitability
This table compares Enanta Pharmaceuticals and Cosmos Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enanta Pharmaceuticals | -89.56% | -64.04% | -20.22% |
| Cosmos Health | -30.41% | -52.85% | -17.87% |
Volatility & Risk
Enanta Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Cosmos Health has a beta of 4.83, suggesting that its stock price is 383% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Enanta Pharmaceuticals and Cosmos Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enanta Pharmaceuticals | 1 | 0 | 7 | 0 | 2.75 |
| Cosmos Health | 1 | 0 | 0 | 0 | 1.00 |
Enanta Pharmaceuticals currently has a consensus target price of $20.29, suggesting a potential upside of 47.64%. Given Enanta Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Enanta Pharmaceuticals is more favorable than Cosmos Health.
Institutional and Insider Ownership
95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.6% of Cosmos Health shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 26.2% of Cosmos Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Cosmos Health beats Enanta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
About Cosmos Health
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
